Date: 2016-02-11
Type of information: Nomination
Compound:
Company: Celgene (USA - NJ)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On February 11, 2016, Celgene announced the election of Mark Alles and Jacqualyn Fouse PhD to its Board of Directors. Mr. Alles has been with Celgene since 2004, most recently serving as President and Chief Operating Officer (COO). Effective March 1, 2016 , Mr. Alles will be promoted to Chief Executive Officer, with Bob Hugin assuming the Executive Chairman role. Before serving as President and COO, Mr. Alles led Celgene's Hematology and Oncology franchise. Dr. Fouse has been with Celgene since 2010, most recently serving as President of Celgene's Hematology and Oncology franchise. Effective March 1, 2016 , Dr. Fouse will be promoted to President and COO. Before serving as President of Celgene's Hematology and Oncology franchise, Dr. Fouse served as Celgene's Chief Financial Officer.
Financial terms:
Latest news:
